National Institutes of Health

Description

This Funding Opportunity Announcement (FOA) encourage DP3 applications from institutions/organizations to allow researchers with access to major clinical nuclear molecular imaging facilities to screen their libraries of existing positron emission tomography (PET) or single photon emission computed tomography (SPECT) neuroimaging agents that are already approved for use in human subjects research in order to find tools to enhance in vivo study of the beta cells of the human pancreatic islet. Diabetes ensues with the loss or dysfunction of beta cells and the inability to monitor their mass is an enormous barrier to understanding the natural history of human diabetes or the course of disease in an individual patient. Because human pancreatic islet beta cells are distinct from those of rodent models of diabetes and yet have many of the neurotransmitter systems found in the human brain, screening of existing human neuroimaging agents directly in human subjects and human tissues may be a cost-efficient way to identify promising beta cell imaging agents.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV